share_log

康哲藥業:2024中期報告

CMS: Interim Report 2024

HKEX ·  Aug 30, 2024 18:04

Summary by Futu AI

康哲藥業(CMS)公佈最新財務報告,顯示營業額同比下降21.7%至人民幣3,611.1百萬元,毛利同比下降25.2%至人民幣2,696.5百萬元,期間溢利同比下降52.8%至人民幣903.4百萬元。公司股份過戶登記分處為香港中央證券登記有限公司。報告期內,公司四款創新藥獲批上市並納入國家醫保目錄,並宣派中期股息每股人民幣0.1507元,同比下降51.9%。公司繼續推動創新產品的商業化進程,並積極開拓東南亞市場,期望進一步提升業績。
康哲藥業(CMS)公佈最新財務報告,顯示營業額同比下降21.7%至人民幣3,611.1百萬元,毛利同比下降25.2%至人民幣2,696.5百萬元,期間溢利同比下降52.8%至人民幣903.4百萬元。公司股份過戶登記分處為香港中央證券登記有限公司。報告期內,公司四款創新藥獲批上市並納入國家醫保目錄,並宣派中期股息每股人民幣0.1507元,同比下降51.9%。公司繼續推動創新產品的商業化進程,並積極開拓東南亞市場,期望進一步提升業績。
CMS (康哲藥業) has announced its latest financial report, which shows a year-on-year decrease of 21.7% in revenue to RMB 3,611.1 million, a 25.2% decrease in gross profit to RMB 2,696.5 million, and a 52.8% decrease in net profit to RMB 903.4 million. The company's stock transfer registration office is Hong Kong Central Securities Registration Co., Ltd. During the reporting period, the company's four innovative drugs were approved for listing and included in the national medical insurance catalog, and a mid-term dividend of RMB 0.1507 per share was declared, a 51.9% decrease compared to the previous year. The company continues to promote the commercialization process of innovative products and actively explore the Southeast Asian market, with the aim of further improving performance.
CMS (康哲藥業) has announced its latest financial report, which shows a year-on-year decrease of 21.7% in revenue to RMB 3,611.1 million, a 25.2% decrease in gross profit to RMB 2,696.5 million, and a 52.8% decrease in net profit to RMB 903.4 million. The company's stock transfer registration office is Hong Kong Central Securities Registration Co., Ltd. During the reporting period, the company's four innovative drugs were approved for listing and included in the national medical insurance catalog, and a mid-term dividend of RMB 0.1507 per share was declared, a 51.9% decrease compared to the previous year. The company continues to promote the commercialization process of innovative products and actively explore the Southeast Asian market, with the aim of further improving performance.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.